Hepion Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2016
Selling, General & Admin	3.32	7.5	9.62	10.35	10.01	Upgrade
Research & Development	0.45	11.85	35.64	33.27	20.4	Upgrade
Operating Expenses	3.76	19.35	45.26	43.62	30.4	Upgrade
Operating Income	-3.76	-19.35	-45.26	-43.62	-30.4	Upgrade
Interest Expense	-0.02	-1.25	-0.01	-0.01	-0.01	Upgrade
Other Non Operating Income (Expenses)	-	-3.17	-	-	-	Upgrade
EBT Excluding Unusual Items	-3.79	-23.76	-45.27	-43.63	-30.41	Upgrade
Impairment of Goodwill	-	-	-	-1.87	-	Upgrade
Asset Writedown	-0.4	-	-	-	-	Upgrade
Other Unusual Items	-4.09	7.6	-0.88	0.41	-2.31	Upgrade
Pretax Income	-8.28	-16.16	-49.34	-45.08	-32.72	Upgrade
Income Tax Expense	-	-2.97	-0.41	-2.88	-	Upgrade
Net Income	-8.28	-13.19	-48.93	-42.2	-32.72	Upgrade
Preferred Dividends & Other Adjustments	-	-	-	3.14	-	Upgrade
Net Income to Common	-8.28	-13.19	-48.93	-45.34	-32.72	Upgrade
Shares Outstanding (Basic)	9	0	0	0	0	Upgrade
Shares Outstanding (Diluted)	9	0	0	0	0	Upgrade
Shares Change (YoY)	7556.50%	54.75%	4.18%	8.45%	-	Upgrade
EPS (Basic)	-0.88	-107.35	-616.07	-594.75	-465.52	Upgrade
EPS (Diluted)	-0.88	-107.35	-616.07	-594.75	-465.52	Upgrade
Free Cash Flow	-3.27	-18.22	-40.9	-34.98	-31.35	Upgrade
Free Cash Flow Per Share	-0.35	-148.23	-515.05	-458.85	-446.07	Upgrade
EBITDA	-3.73	-19.32	-45.19	-43.54	-30.32	Upgrade
D&A For EBITDA	0.03	0.03	0.07	0.08	0.09	Upgrade
EBIT	-3.76	-19.35	-45.26	-43.62	-30.4	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.